Key Takeaways Neumora Therapeutics reported its experimental depression drug didn't meet expectations, and shares plunged.The ...
Patients who received the drug, called navacaprant, showed no more improvement in depressive symptoms than people who ...
In a highly anticipated readout for the kappa opioid receptor class in major depressive disorder, Neumora’s navacaprant ...
Neuroscience drug developer Neumora Therapeutics released highly anticipated results from the first of three Phase 3 trials ...
Neumora Therapeutics Inc.’s shares plummeted after the company’s experimental drug failed to show a benefit in a final-stage ...
It is the first drug to have an impact on the symptoms of manic depression since the introduction of lithium more than 50 years ago. In international trials over the past two years, daily doses of ...
Those on the extreme end of the depression spectrum face symptoms that impact their daily activities too and not just their ...
The history of weight loss medicines reads like a Greek tragedy. However, the biology behind the new GLP-1 agonists suggests ...
Vagus nerve stimulation therapy improved the symptoms of treatment-resistant depression for nearly 500 participants in a ...
Doctors should think twice before prescribing drug therapies when faced with someone battling depression, as exercise may be more effective, according to a new study. A meta-analysis of 218 ...
Millions of Brits could be at risk of medication-induced depression from taking heartburn pills and range of other common routine medications. Proton pump inhibitors (PPIs), a type of medication ...
approved by the FDA for treatment-resistant depression in 2019 and for MDD patients at risk of suicide earlier this year – but is thought to lack some of the psychoactive effects of these drugs.